What does CSL Behring do?

CSL Behring LLC. develops, manufactures, and markets protein-based therapies. The Company offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing plasma-derived and recombinant therapies.

Is CSL (CSL) a good stock to buy?

The stock has dropped 16.7 per cent from its 2021 closing high of $318. Despite this, CSL’s 12-month consensus target price from analysts via Bloomberg sits at $316.60. More than 80 per cent of analysts who cover the stock have a positive view of the company, according to the Bloomberg consensus view.

How much does CSL Behring cost?

Drugmaker CSL Behring announced the $3.5 million price tag shortly after the FDA approval, saying its drug would ultimately reduce health care costs because patients would have fewer bleeding incidents and need fewer clotting treatments. The price appeared to exceed that of several other gene therapies priced upwards of $2 million.

Is CSL a biopharmaceutical company?

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants.